MeTA Peru

Medicines Transparency Alliance20/04/23 1

MeTA Peru

Germán Rojas, Technical SecretaryLeda M. Perez, Consultant to MeTA in Peru


Multi-stakeholder process

A commitment to engage– Received a commitment from the MoH in early 2008 to participate in MeTA– Participation of public and private sectors and civil society in MeTA global

launch of May, 2008

A commitment to proceed– Birth of the Grupo Impulsor, June 2008– MeTA Peru National Forum, November, 2008– Consolidation of Executive Committee and National Council between

November, 2008 and February, 2009– Refinement of MeTA Peru national work plan, February, 2009-February, 2010

A commitment to implement– Executive Committee continues to meet weekly to make decisions relative to

work plan implementation– National Council meets every two months to assess progress on work plan

Medicines Transparency Alliance

Major achievements and successes

All sectors remain at the table!– Continuous nature of multi stakeholder process– Communication has changed as a result of MeTA

Progress on key areas of implementation– Price Observatory– Public purchases study– Development of Centers for Medicines Information

Agreement on key areas to be implemented– Development of a national generics policy– Development of baseline data studies, i.e., pharmaceutical sector scan and

multi stakeholder process evaluation– Development of software for price observatory– Development of Website/communications plan

20/04/23 3


Overall challenges

The multi stakeholder process takes time– Sectors are working together which may have never had a history of

collaboration– Without trust and relationships it is impossible to move the agenda forward.– Must adapt to new structures, i.e., Executive Committee, National Council,

administrative and technical secretariats

The Executive Committee and National Council lead this process and not the Technical or Administrative Secretariats– This means that there are many minds at work and the Technical and

Administrative Secretariats are beholden to the will of these voluntary bodies and not the other way around

20/04/23 4


Lessons Learned

The multi stakeholder process may be a useful manner of creating transparency and improving decision-making in the pharmaceutical sector. However,– Investments in relationship- and trust-building are essential– Such a process is difficult anywhere in the world, but may be particularly

challenging in environments whose governments have been historically centralized.

While transparency in information about medicines and process is important, we must be careful that the mechanisms put in place do not create greater bureaucracies

There is value in a shared space between civil society, government and private sector to discuss common issues of concern.

20/04/23 5


Lessons Learned

20/04/23 6

PUBLIC SECTOR

CIVILSOCIETIES

PRIVATESECTOR

• MINSA• EsSalud• Defensoría del Pueblo• Facultad de Medicina de la UNMSM • Gobiernos Regionales: Arequipa, Huánuco, Piura

• Asociación Nacional de Laboratorios Farmacéuticos– ALAFARPE• Asociación Nacional de Industrias Farmacéuticas – ADIFAN• Comisión de Salud de Cámara de Comercio de Lima (COMSALUD)• Asociación Peruana de Entidades Prestadoras de Salud (APEPS)

• Colegio Médico del Perú • Acción Internacional para la Salud • Foro Salud • Red Peruana de Pacientes y Usuarios


Lessons Learned

20/04/23 7

PresidentVice-President15 Members

MoHOmbudsmanHAIMedical College of PeruALAFARPE

National Council MeTA Peru

Executive Committee MeTA Peru

Technical Secretariat

Communicator

AdministrativeSecretariat

Support: International consultant


Thank you

German Rojas, Technical Secretary

Leda M. Perez, Consultant to MeTA in Peru

Email: [email protected] and [email protected]

Mobile number: 511 99566 5509 (Leda) 511 999378102 (Germán)

Skype: leda568 and grojas3000

Website: www.metaperu.org

MeTA Peru

Documents

Transcript of MeTA Peru